Therefore, known GalR antagonists may have multiple targets and it would be of high interest to develop an antagonist for treatment of depression that selectively target the GalR1–GalR2 heteromer postulated to be the galanin N-terminal fragment receptor. This evidence concerns the gene GALR1 and major depressive disorder.